Medibact GuidesShop at Medibact

Stacking Module

Retatrutide Stacking Module

Retatrutide is a triple agonist — GIP, GLP-1 and glucagon receptors — which means it covers more incretin mechanisms in one molecule than anything else here. It is also entirely investigational, with no approved label anywhere, so unlike semaglutide and tirzepatide there is not even a prescribing document to reason from.

Retatrutide Guide at MedibactRetatrutide calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking Retatrutide

  • Retatrutide agonises three receptors in one molecule. Adding another incretin agonist is redundant across at least one of them, usually two.
  • It is unapproved everywhere. There is no label, no approved dosing, and no post-marketing safety record — only Phase 2 trial data.
  • Its glucagon-receptor component is the mechanism the others lack, and it is also the one with the least characterised long-term profile.
  • No controlled trial has studied retatrutide combined with anything.

Combinations in detail

Amylin pairing (reported)

Retatrutide + Cagrilintide
Why it is proposed
Amylin agonism is a distinct pathway from all three of retatrutide's receptors, so on mechanism this is not a collision.
What is reported in practice
Community-reported only; no trial has evaluated it.
Cautions specific to this combination
Two investigational compounds, neither approved, with no combination data and additive gastrointestinal effects. This is the least-evidenced combination in the metabolic group.

Lean-mass preservation discussion

Retatrutide + BPC-157
Why it is proposed
Community reasoning about offsetting lean-mass loss with an unrelated repair compound.
What is reported in practice
Separate vials, separate schedules.
Cautions specific to this combination
No evidence for the premise, and retatrutide's own safety profile outside trials is uncharacterised.

What to avoid, and why

  • Adding semaglutide or tirzepatide — retatrutide already agonises GLP-1 and GIP.
  • Reading Phase 2 weight-loss figures as applying to any combination, or as an approved efficacy claim.
  • Assuming an unapproved compound's absence of documented interactions means absence of interactions — it means nobody has looked.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.